Oragenics (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing neurological therapeutics, has been granted an extension by NYSE Regulation to regain compliance with NYSE American continued listing standards through Feb. 25, 2028. The approval, announced in a press release, allows the company to maintain its exchange listing while implementing measures intended to strengthen its financial position, subject to meeting plan milestones and ongoing review requirements.
The extension follows a noncompliance notice issued on Aug. 26, 2026, after Oragenics reported stockholders’ equity of $3.7 million as of June 30, 2026, and losses from continuing operations and/or net losses in its five most recent fiscal years. The company submitted its compliance plan on Sept. 25, 2026, and received formal acceptance on Nov. 11. CEO Janet Huffman said the extension will allow Oragenics to continue pursuing its strategic priorities, capital-raising initiatives and investment strategies aimed at enhancing long-term shareholder value.
For readers and investors, the decision is significant because it removes the immediate threat of delisting and gives the company a runway to execute its business plan. Maintaining the NYSE American listing is important for access to capital and for the visibility that comes with trading on a national exchange. The company’s ability to meet the milestones in its plan will be closely watched, as failure to do so could revive listing concerns.
Oragenics is developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being advanced as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
The broader implication is that the extension supports the continuation of a drug-development program targeting significant unmet medical needs in neurological care. For the biotechnology sector, it illustrates how exchange compliance processes can affect clinical-stage companies that carry losses while investing in research. Investors can follow the company’s latest news and updates through its newsroom at https://ibn.fm/OGEN, and the full press release is available at https://ibn.fm/LiPlM. More information about the company is available at oragenics.com.
The announcement was distributed through BioMedWire, a communications platform focused on biotechnology and life sciences that is part of the Dynamic Brand Portfolio at IBN. Such distribution channels help clinical-stage companies reach investors and media, and readers should review the full terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer when evaluating company announcements.
